logo

France Oral Anti-Diabetic Drug Market Size (2024 - 2029)

The France oral anti-diabetic drug market is experiencing growth driven by increasing diabetes and obesity rates, heightened awareness of diabetic care, and advancements in healthcare technology. The market's expansion is further supported by the critical role of diabetes medications in managing blood glucose levels, especially highlighted during the COVID-19 pandemic when diabetes was identified as a significant risk factor for severe outcomes. The prevalence of diabetes, covered extensively by France's statutory health insurance, underscores the importance of these medications in the healthcare system.

Home Market Analysis Healthcare Research Medical Devices Research France Oral Anti-Diabetic Drug Market Market Size

Market Size of France Oral Anti-Diabetic Drug Industry

France Oral Anti-Diabetic Drug Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Historical Data Period 2019 - 2022
CAGR > 4.00 %

Major Players

France Oral Anti-Diabetic Drug Market Major Players

*Disclaimer: Major Players sorted in no particular order

France Oral Anti-Diabetic Drug Market Analysis

France's Oral Anti-Diabetic Drug Market is expected to register a CAGR of more than 4% during the forecast period and revenue of USD 0.7 billion in the current year.

Diabetes mellitus was one of the most important risk factors for a severe course of COVID-19. This risk was thought to be impacted by numerous characteristics that are common in diabetes mellitus. Age, proinflammatory and hypercoagulable state, hyperglycemia, hypertension, cardiovascular disease, chronic renal disease, and obesity are all factors. During the COVID-19 pandemic, diabetes was early identified as a risk factor for poor outcomes. As a result, controlling or postponing instances of type 2 diabetes has become more crucial than ever. Diabetic medications were considered prospective treatments for diabetic people infected with SARS-CoV-2 during the COVID-19 pandemic.

Diabetes meds are medications designed to stabilize and manage blood glucose levels in diabetics. Diabetes medications are often used to treat the disease. Diabetes medications are classified into several categories. Each type of drug has a unique method of action for lowering blood sugar. A medication may function by inducing the pancreas to produce and release more insulin, reducing the liver's capacity to produce and release sugar, inhibiting the action of enzymes in the intestines that break down carbs, and many other mechanisms. It also raises cell sensitivity to insulin, decreasing the kidneys' ability to take in sugar and increasing the quantity of sugar exiting the body in urine.

Diabetes is the greatest frequency of any chronic ailment covered entirely by France's statutory health insurance (SHI), and the number of insured patients has more than quadrupled in the last decade. Diabetes is becoming more common among people of all ages in France, which can be ascribed to an increasingly obese population, bad diets, and sedentary lifestyles. Thus, rising diabetes and obesity rates, increased knowledge of diabetic care, increased healthcare spending, and technological improvements are a few of the drivers driving the France oral anti-diabetes drugs market.

France Oral Anti-Diabetic Drug Industry Segmentation

Orally administered antihyperglycemic drugs reduce blood glucose levels. They are often used in type 2 diabetes care. France Oral Anti-Diabetic Drug Market is segmented into drugs (Biguanides, Alpha-glucosidase inhibitors, Dopamine-D2 receptor agonists, Sodium-glucose Cotransport-2 (SGLT-2) inhibitor, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Sulfonylureas, and Meglitinides). The report offers the value (in USD million) and volume (in Units million) for the above segments.

Oral Anti-diabetic drugs
Biguanides
Metformin
Alpha-Glucosidase Inhibitors
Alpha-Glucosidase Inhibitors
Dopamine D2 receptor agonist
Bromocriptin
SGLT-2 inhibitors
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
DPP-4 inhibitors
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina(Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas
Sulfonylureas
Meglitinides
Meglitinides
Need A Different Region Or Segment?
Customize Now

France Oral Anti-Diabetic Drug Market Size Summary

The France oral anti-diabetic drug market is poised for steady growth, driven by the increasing prevalence of diabetes and obesity, alongside heightened awareness and healthcare expenditure. The market is characterized by a diverse range of oral medications designed to manage blood glucose levels in individuals with type 2 diabetes. These medications operate through various mechanisms, such as enhancing insulin secretion, improving insulin sensitivity, and reducing glucose production in the liver. The DPP-4 inhibitors segment is expected to lead the market, offering additional benefits beyond glucose regulation, including potential improvements in cardiovascular and hepatic health. The French healthcare system's comprehensive coverage of diabetes under statutory health insurance further supports market expansion, making oral anti-diabetic drugs a preferred choice due to their ease of use and cost-effectiveness compared to insulin.

The market landscape is dominated by major global players like Eli Lilly, AstraZeneca, Sanofi, and Janssen Pharmaceuticals, who are actively engaged in innovation and development of new diabetes medications. The introduction of new drug classes, such as SGLT-2 inhibitors, has expanded treatment options, addressing the progressive nature of diabetes. Despite the challenges posed by therapeutic inertia and the need for improved patient and physician education, the market presents significant opportunities for growth. Regulatory bodies are closely monitoring the market, as seen with the French drug safety agency's actions regarding the use of diabetes medications for weight loss. This regulatory scrutiny, coupled with ongoing research and public awareness initiatives, underscores the dynamic nature of the France oral anti-diabetic drug market.

Explore More

France Oral Anti-Diabetic Drug Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Oral Anti-diabetic drugs

      1. 2.1.1 Biguanides

        1. 2.1.1.1 Metformin

      2. 2.1.2 Alpha-Glucosidase Inhibitors

        1. 2.1.2.1 Alpha-Glucosidase Inhibitors

      3. 2.1.3 Dopamine D2 receptor agonist

        1. 2.1.3.1 Bromocriptin

      4. 2.1.4 SGLT-2 inhibitors

        1. 2.1.4.1 Invokana (Canagliflozin)

        2. 2.1.4.2 Jardiance (Empagliflozin)

        3. 2.1.4.3 Farxiga/Forxiga (Dapagliflozin)

        4. 2.1.4.4 Suglat (Ipragliflozin)

      5. 2.1.5 DPP-4 inhibitors

        1. 2.1.5.1 Onglyza (Saxagliptin)

        2. 2.1.5.2 Tradjenta (Linagliptin)

        3. 2.1.5.3 Vipidia/Nesina(Alogliptin)

        4. 2.1.5.4 Galvus (Vildagliptin)

      6. 2.1.6 Sulfonylureas

        1. 2.1.6.1 Sulfonylureas

      7. 2.1.7 Meglitinides

        1. 2.1.7.1 Meglitinides

France Oral Anti-Diabetic Drug Market Size FAQs

The France Oral Anti-Diabetic Drug Market is projected to register a CAGR of greater than 4% during the forecast period (2024-2029)

Astrazeneca, Astellas, Sanofi, Eli Lilly and Janseen are the major companies operating in the France Oral Anti-Diabetic Drug Market.

France Oral Anti-Diabetic Drug Market Report Snapshots

France Oral Anti-Diabetic Drug Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)